Document Detail


Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
MedLine Citation:
PMID:  23380861     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: To date, limited information is available describing the incidence and impact of de novo donor-specific anti-human leukocyte antigen (HLA) antibodies (dnDSA) in the primary renal transplant patient. This report details the dnDSA incidence and actual 3-year post-dnDSA graft outcomes.
METHODS: The study includes 189 consecutive nonsensitized, non-HLA-identical patients who received a primary kidney transplant between March 1999 and March 2006. Protocol testing for DSA via LABScreen single antigen beads (One Lambda) was done before transplantation and at 1, 3, 6, 9, and 12 months after transplantation then annually and when clinically indicated.
RESULTS: Of 189 patients, 47 (25%) developed dnDSA within 10 years. The 5-year posttransplantation cumulative incidence was 20%, with the largest proportion of patients developing dnDSA in the first posttransplantation year (11%). Young patients (18-35 years old at transplantation), deceased-donor transplant recipients, pretransplantation HLA (non-DSA)-positive patients, and patients with a DQ mismatch were the most likely to develop dnDSA. From DSA appearance, 9% of patients lost their graft at 1 year. Actual 3-year death-censored post-dnDSA graft loss was 24%.
CONCLUSION: We conclude that 11% of the patients without detectable DSA at transplantation will have detectable DSA at 1 year, and over the next 4 years, the incidence of dnDSA will increase to 20%. After dnDSA development, 24% of the patients will fail within 3 years. Given these findings, future trials are warranted to determine if treatment of dnDSA-positive patients can prevent allograft failure.
Authors:
Matthew J Everly; Lorita M Rebellato; Carl E Haisch; Miyuki Ozawa; Karen Parker; Kimberly P Briley; Paul G Catrou; Paul Bolin; William T Kendrick; Scott A Kendrick; Robert C Harland; Paul I Terasaki
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation     Volume:  95     ISSN:  1534-6080     ISO Abbreviation:  Transplantation     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  410-7     Citation Subset:  IM    
Affiliation:
1 Terasaki Foundation Laboratory, Los Angeles, CA. 2 Department of Pathology, Brody School of Medicine at ECU, Greenville, NC. 3 Department of Surgery, Brody School of Medicine at ECU, Greenville, NC. 4 One Lambda, Los Angeles, CA. 5 Department of Medicine, Brody School of Medicine at ECU, Greenville, NC. 6 Eastern Nephrology and Associates, Greenville, NC. 7 Address correspondence to: Dr. Matthew J. Everly, Terasaki Foundation, 11570 West Olympic Boulevard, Los Angeles, CA 90064.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human de...
Next Document:  Isoform 111 of Vascular Endothelial Growth Factor (VEGF111) Improves Angiogenesis of Ovarian Tissue ...